General MedicationsINTRAVENOUSGeneric
VARITHENA
POLIDOCANOL
Standard Dose
77.5MG/7.75ML (10MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview VARITHENA is listed in Drugs@FDA under application 205098 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient POLIDOCANOL Form and strength SOLUTION;INTRAVENOUS - 77.5MG/7.75ML (10MG/ML) Sponsor PROVENSIS Submission history Latest submission status date: 2019-08-21 00:00:00.
Structured Monograph
Clinical summary
Approval overview VARITHENA is listed in Drugs@FDA under application 205098 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient POLIDOCANOL Form and strength SOLUTION;INTRAVENOUS - 77.5MG/7.75ML (10MG/ML) Sponsor PROVENSIS Submission history Latest submission status date: 2019-08-21 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.